(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.47%) $27.23
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
4.40% $ 10.57
@ $7.33
Ausgestellt: 14 Feb 2024 @ 19:17
Rendite: 44.20%
Vorheriges Signal: Feb 14 - 15:30
Vorheriges Signal:
Rendite: 6.23 %
Live Chart Being Loaded With Signals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases...
Stats | |
---|---|
Tagesvolumen | 193 217 |
Durchschnittsvolumen | 475 155 |
Marktkapitalisierung | 273.83M |
EPS | $0 ( 2024-03-06 ) |
Nächstes Ertragsdatum | ( $-1.080 ) 2024-05-08 |
Last Dividend | $0.0690 ( 2017-09-28 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.740 |
ATR14 | $0.0200 (0.19%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Buy | 972 | Common Stock |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
2024-02-26 | Weiner David B. | Sell | 972 | Restricted Stock Unit |
INSIDER POWER |
---|
61.43 |
Last 100 transactions |
Buy: 3 683 868 | Sell: 932 723 |
Volumen Korrelation
Inovio Pharmaceuticals Korrelation
10 Am meisten positiv korreliert | |
---|---|
AKTX | 0.966 |
LSXMA | 0.961 |
LSXMK | 0.961 |
STRO | 0.95 |
TUEM | 0.948 |
ASPU | 0.946 |
OPHC | 0.943 |
CMLS | 0.942 |
WATT | 0.942 |
AADI | 0.941 |
10 Am meisten negativ korreliert | |
---|---|
CPTA | -0.952 |
SGEN | -0.946 |
RAM | -0.936 |
GPACU | -0.936 |
NVSA | -0.936 |
COCO | -0.934 |
MLAI | -0.932 |
PESI | -0.928 |
PTOC | -0.928 |
FRSG | -0.927 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Inovio Pharmaceuticals Korrelation - Währung/Rohstoff
Inovio Pharmaceuticals Finanzdaten
Annual | 2023 |
Umsatz: | $832 010 |
Bruttogewinn: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2023 |
Umsatz: | $832 010 |
Bruttogewinn: | $-2.67M (-321.09 %) |
EPS: | $-6.09 |
FY | 2022 |
Umsatz: | $10.26M |
Bruttogewinn: | $4.77M (46.44 %) |
EPS: | $-14.47 |
FY | 2021 |
Umsatz: | $1.77M |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.450 |
Financial Reports:
No articles found.
Inovio Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0690 | 2017-06-28 |
Last Dividend | $0.0690 | 2017-09-28 |
Next Dividend | $0 | N/A |
Payout Date | 2017-10-16 | |
Next Payout Date | N/A | |
# dividends | 4 | -- |
Total Paid Out | $0.276 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.17 | -- |
Div. Sustainability Score | 2.18 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0.449 | -- |
Year | Amount | Yield |
---|---|---|
2017 | $0.276 | 3.90% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 3 430.55 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 16.50 | 1.200 | 10.00 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 18.29 | 1.500 | 10.00 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.47 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.336 | 1.500 | 9.24 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.175 | -1.500 | 7.09 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -241.59 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -2.90 | -5.81 | [0 - 20] |
debtEquityRatioTTM | 0.257 | -1.500 | 8.97 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | -38.10 | 1.000 | -10.00 | -10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | -173.00 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -4.37 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.00481 | 0.800 | -3.30 | -2.64 | [0.5 - 2] |
Total Score | 2.18 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 0.0844 | 1.000 | -0.0925 | 0 | [1 - 100] |
returnOnEquityTTM | 18.29 | 2.50 | 10.00 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -5.81 | 2.00 | -1.936 | -5.81 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -5.80 | 2.00 | -1.932 | -3.86 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0000652 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -158.77 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -1.283 |
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.